Abivax S.A. (ABVX)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
- Ticker
- ABVX
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- 52-week range
- $69.81 - $148.83
Valuation
- Share price
- $85.73 (close of Nov 6, 2026)
- P/E (TTM)
- -16.13x
- Price to book
- 13.17x
- Price to free cash flow
- -37.18x
Price performance
| Period | Change |
|---|---|
| 1 day | +1.84% |
| 5 days | -0.99% |
| 1 month | -2.82% |
| 3 months | -34.05% |
| 6 months | -32.25% |
| Year to date | -36.43% |
| 1 year | -17.49% |
| 3 years | +746.30% |
| All time | +932.89% |
Short interest
- As of
- Oct 15, 2026
- Short % of float
- 8.39%
- Shares short
- 7.25M
- Days to cover
- 6.08
- Change since prior report
- -6.71%
- Source
- FINRA consolidated short interest
Profitability and growth
- Return on equity
- -73.84%
- Return on invested capital
- -53.83%
- Return on assets
- -57.52%
- Return on capital employed
- -47.20%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -2.69%
- Current ratio
- 8.75x
- Net debt to EBITDA
- 1.71x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Shares outstanding
- 69.53M
Margins and returns by year
| Period end | Return on equity | Return on capital |
|---|---|---|
| 2025-12-31 | -73.84% | -53.83% |
| 2024-12-31 | - | -125.40% |
| 2023-12-31 | -75.37% | -50.14% |
| 2022-12-31 | - | -139.88% |
| 2021-12-31 | -163.69% | -159.64% |
Investor relations
Next earnings report
- Next confirmed report
- Dec 21, 2026
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-09-21 | Jun 2026 | - |
| 2026-05-22 | Mar 2026 | - |
| 2026-03-23 | Dec 2025 | - |
| 2025-12-15 | Sep 2025 | - |
| 2025-09-08 | Jun 2025 | - |
| 2025-06-02 | Mar 2025 | - |
| 2024-04-02 | - | - |
Filings and sources
- Company website
- abivax.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades